Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co Interest Expense

The Interest Expense of Harbin Pharmaceutical Group Co (600664.SS) as of Nov 20, 2026 is -30.18 M CNY. In the previous year, Interest Expense was -15.12 M CNY — a change of 99.63% (lower).

Interest Expense

-30.18 MCNY

YoY

99.63%

Last updated:

Interest Expense of Harbin Pharmaceutical Group Co is 2024 -30.18 M CNY. Interest Expense of Harbin Pharmaceutical Group Co was 2023 -15.12 M CNY. It decreases by 99.63% lower compared to the previous year.

The Harbin Pharmaceutical Group Co Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2017
83.00 M CNY
Jan 1, 2018
20.00 M CNY
Jan 1, 2019
93.00 M CNY
Jan 1, 2020
-9.00 M CNY
Jan 1, 2021
-86.66 M CNY
Jan 1, 2022
-52.81 M CNY
Jan 1, 2023
-15.12 M CNY
Jan 1, 2024
-30.18 M CNY
The Harbin Pharmaceutical Group Co Interest Expense history
YEARInterest ExpenseYoY
-30.18 MCNY+99.63%
-15.12 MCNY-71.38%
-52.81 MCNY-39.06%
-86.66 MCNY+862.91%
-9.00 MCNY-109.68%
93.00 MCNY+365.00%
20.00 MCNY-75.90%
83.00 MCNY+167.74%
31.00 MCNY-18.42%
38.00 MCNY-28.30%
53.00 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

Interest Expense of Harbin Pharmaceutical Group Co is -30.18 M CNY in 2024.

Interest Expense of Harbin Pharmaceutical Group Co changed from -15.12 M CNY to -30.18 M CNY, representing a 99.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Harbin Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Harbin Pharmaceutical Group Co

All Key Metrics — Harbin Pharmaceutical Group Co